Abstract
To assess clearance mechanisms of atrial and brain natriuretic peptides in the circulation, we examined the effects of a neutral endopeptidase (NEP) inhibitor and a clearance receptor ligand on plasma concentrations of the peptides in normal rats. Plasma concentrations of endogenous α-rat atrial natriuretic peptide (α-rANP) were not significantly elevated by intravenous infusion of a NEP inhibitor, phosphoramidon, but were elevated threefold by intravenous infusion of a clearance receptor ligand, des(Gln18-Gly22)-rANP(4−23)-NH2 [C-ANF(4−23)]. On the other hand, the clearance of α-rANP given intravenously at the pharmacological dose, 600 pmol/ min/kg for 2 min, was decreased to one-third by the administration of phosphoramidon, although the administration of C-ANF(4−23) did not significantly decrease the clearance. The clearance of rat brain natriuretic peptide (rBNP) given at 600 pmol/min/kg for 2 min was approximately 38% lower than that of α-rANP. The effect of phosphoramidon on the clearance of rBNP was not significant and was similar to that of C-ANF(4−23). These results suggest that clearance receptor is involved in the clearance of the physiological levels of α-rANP and that NEP plays a major role in the clearance of a pharmacological dose of α-rANP, at which clearance receptors are thought to be saturated, and also indicate a pharmacokinetic difference between α-rANP and rBNP.
Similar content being viewed by others
REFERENCES
Y. Saito, K. Nakao, K. Nishimura, A. Sugawara, K. Okumura, K. Obata, R. Sonoda, T. Ban, H. Yasue, and H. Imura. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: Beneficial effects on left ventricular function. Circulation 76:115–124 (1987).
K. Nakao, A. Sugawara, N. Morii, M. Sakamoto, T. Yamada, H. Itoh, S. Shiono, Y. Saito, K. Nishimura, T. Ban, K. Kangawa, H. Matsuo, and H. Imura. The pharmacokinetics of α-human natriuretic polypeptide in healthy subjects. Eur. J. Clin. Pharmacol. 31:101–103 (1987).
T. Maack, M. Suzuki, F. A. Almedia, D. Nussenzveig, R. M. Scarborough, G. A. McEnroe, and J. A. Lewicki. Physiological role of silent receptors of atrial natriuretic factor. Science 238:675–678 (1987).
S. Suga, K. Nakao, K. Hosoda, M. Mukoyama, Y. Ogawa, G. Shirakami, H. Arai, Y. Saito, Y. Kambayashi, K. Inouye, and H. Imura. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 130:229–239 (1992).
A. J. Kenny and A. L. Stephenson. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 232:1–8 (1988).
Y. Vanneste, A. Michel, R. Dimaline, T. Majdovski, and M. Deschodt-Vanckman. Hydrolysis of α-human natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11: Evidence for a novel cleavage site. Biochem. J. 254:531–537 (1988).
Y. Hashimoto, K. Nakao, N. Hama, M. Mukoyama, H. Imura, M. Yasuhara, and R. Hori. Pharmacokinetics of brain natriuretic peptide in rats. Chem. Pharm. Bull. 40:1650–1652 (1992).
R. L. Webb, G. D. Yasay, C. McMartin, R. B. McNeal, and M. B. Zimmerman. Degradation of atrial natriuretic peptide: Pharmacologic effects of protease EC 24.11 inhibition. J. Cardiovasc. Pharmacol. 14:285–293 (1989).
R. Hori, K. Inui, H. Saito, Y. Matsukawa, K. Okumura, K. Nakao, N. Morii, and H. Imura. Specific receptors for atrial natriuretic polypeptide on basolateral membranes isolated from rat renal cortex. Biochem. Biophys. Res. Commun. 129:773–779 (1985).
Y. Ogawa, K. Nakao, M. Mukoyama, G. Shirakami, H. Itoh, K. Hosoda, Y. Saito, H. Arai, S. Suga, M. Jougasaki, T. Yamada, Y. Kambayashi, K. Inouye, and H. Imura. Rat brain natriuretic peptide—tissue distribution and molecular form. Endocrinology 126:2225–2227 (1990).
W. H. Press, B. P. Flannery, S. A. Teukolsky, and W. T. Vetterling. Numerical Recipes: The Art of Scientific Computing, Cambridge University Press, New York, 1986, pp. 289–293.
P. J. S. Chiu, G. Tetzloff, M. T. Romano, C. J. Foster, and E. J. Sybertz. Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am. J. Physiol. 260:R208–R216 (1991).
K. Nakao, H. Itoh, Y. Kambayashi, K. Hosoda, Y. Saito, T. Yamada, M. Mukoyama, H. Arai, G. Shirakami, S. Suga, M. Jougasaki, Y. Ogawa, N. Minamino, K. Inouye, and H. Imura. Rat brain natriuretic peptide: Isolation from rat heart and tissue distribution. Hypertension 15:774–778 (1990).
N. Yokota, Y. Yamamoto, M. Aburaya, K. Kitamura, T. Eto, K. Kangawa, N. Minamino, H. Matsuo and K. Tanaka. Increased secretion of brain natriuretic peptide and atrial natriuretic peptide, but not sufficient to induce natriuresis in rats with nephrotic syndrome. Biochem. Biophys. Res. Commun. 174:128–135 (1991).
M. Gagelmann, D. Hock, and W. G. Frossmann. Urodilatin (CDD/ANP95-126) is not biologically inactivated by a peptidase from dog kidney membrane in contrast to atrial natriuretic peptide/cardiodilatin (α-hANP/CDD99-126). FEBS Lett. 233:249–254 (1988).
J. A. Norman, D. Little, M. Bolgar, and D. Donata. Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem. Biophys. Res. Common. 175:22–30 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hashimoto, Y., Nakao, K., Hama, N. et al. Clearance Mechanisms of Atrial and Brain Natriuretic Peptides in Rats. Pharm Res 11, 60–64 (1994). https://doi.org/10.1023/A:1018941626731
Issue Date:
DOI: https://doi.org/10.1023/A:1018941626731